Introduction {#S0001}
============

Colon cancer, a principle malignancy of the alimentary canal, ranks third among malignant tumors in terms of morbidity worldwide.[@CIT0001],[@CIT0002] The relevant studies reveal that more than 1 million people developed colon cancer each year, and the disease-specific mortality rate in developed countries is approximately 45%.[@CIT0003] Mortality of colon cancer is on the rise due to changes in diet and lifestyle.[@CIT0004],[@CIT0005] Although colon cancer treatment options (e.g.surgery, chemoradiotherapy, and immunotherapy) have been greatly improved, the 5-year survival rate remains as high as 64.9%.[@CIT0006]

It has been extensively documented that the immune system plays an important role in cancer. The immune response is the process of interaction between many specific cells that may affect the clinical outcome of colon cancer.[@CIT0007] It has been reported that the composition and function of tumor-infiltrating immune cells (TIICs) varies with the host immune status and has potential prognostic value. Notably, they could be effectively targeted by drugs and affect the clinical outcomes of patients. CIBERSORT is a gene expression-based deconvolution algorithm that uses a set of barcode gene expression values to characterize immune cell composition. Compared with traditional immunohistochemistry and flow cytometry methods, CIBERSORT algorithm can comprehensively, quickly and accurately infer the relative proportion of 22 types of invasive immune cells in tumors.[@CIT0008] Given the superiority of this method, a large number of studies have recently used this method to investigate the effect of 22 tumor immune cell subtypes on prognosis.[@CIT0009]--[@CIT0012]

The purpose of this study is to calculate the infiltration extent of 22 immune cells in colon cancer and investigate the effects of 22 TIICs on the prognosis of patients with colon cancer via the CIBERSORT algorithm. Furthermore, an immune risk score model and a nomogram model are constructed to predict the survival of colon cancer.

Materials and Methods {#S0002}
=====================

Data Acquisition {#S0002-S2001}
----------------

We identified and downloaded the transcriptome data of patients with colon cancer from the TCGA database, including 39 cases of normal tissue and 369 cases of tumor tissue. Additionally, relevant clinical information of 369 colon cancer patients were obtained such as age, gender, stage, tumor & Lymph node & metastasis stage, survival status, mutations, microsatellite status, and survival duration. Four GEO datasets (GSE29623, GSE39582, GSE72969, GSE103479) were combined as one independent validation set with 856 cases of colon cancer patients ([<https://www.ncbi.nlm>]{.ul}. nih.gov/geo/). Finally, "limma" package in R software was utilized to correct the transcriptome data we have downloaded.

Assessment of Immune Infiltration {#S0002-S2002}
---------------------------------

CIBERSORT was a deconvolution algorithm that used 547 tag gene expression values to characterize the composition of immune cells in tissues. In this study, we used this algorithm to estimate the relative proportion of 22 infiltrating immune cells in the corrected transcriptome data of colon cancer. We uploaded the corrected transcriptome data to the CIBERSORT website ([<http://cibersort.stanford.edu>]{.ul}) and set the algorithm to 1000 rows. P \< 0.05 was considered to be statistically significant.

Statistical Analysis {#S0002-S2003}
--------------------

All analyses were performed using R 3.6.1. All statistical tests were two-sided, and P value \<0.05 was considered statistically significant. Continuous variables that conformed to the normal distribution were compared with the use of independent *t* test for comparison between groups, while continuous variables with skewed distribution were compared with the Mann--Whitney *U*-test. The correlation matrix was constructed by R software based on Pearson correlation coefficient. The relationship between immune cell infiltration and overall survival was analyzed through the Kaplan--Meier curve which was evaluated by Log-rank test. Time-dependent ROC curves were used to analyze the sensitivity and specificity of the recurrence prediction model. The univariate regression model was used to analyze the effects of individual variables on survival. The least absolute shrinkage and selection operator (LASSO) ﻿Cox regression model was used to confirm independent impact factors associated with survival. The nomogram was constructed with the regression coefficients based on the ﻿Cox analysis.

Results {#S0003}
=======

Distribution of Tumor-Infiltrating Immune Cells {#S0003-S2001}
-----------------------------------------------

In this study, the dataset included 369 cases of colon cancer samples. The clinicopathological characteristics of these samples are shown in [Table 1](#T0001){ref-type="table"}. The composition of TIIC in colon cancer samples and the correlation between immune cells are shown in [Figure 1A](#F0001){ref-type="fig"} and [1B](#F0001){ref-type="fig"}, respectively. We also demonstrated a close relationship between each type of TIIC via Pearson correlation coefficient ([Figure 1C](#F0001){ref-type="fig"}). Furthermore, we revealed that there were large differences in the composition of TIIC between normal tissue and colon cancer tissue ([Figure 1D](#F0001){ref-type="fig"}). B cells naive, Plasma cells, T cells delta gamma, NK cells activated, Monocytes, Macrophages M2, mast cells resting were decreased whereas T cells CD4 memory activated, T cells follicular helper, NK cells resting, Macrophages M0, mast cells activated were increased in colon cancer tissues compared with healthy bowel tissues. We further investigated the proportion of each TIIL in different pathological stages. We demonstrated that plasma cells, Macrophages M0 and T cells follicular helper were most significantly associated with development of pathological stages ([Figure 2](#F0002){ref-type="fig"}).Table 1Clinical Characteristics of Patients Involved in the StudyAge≤65150\>65219GenderFemale174Male195StageStage I64Stage II148Stage III103Stage IV54T stageT17T265T3255T442M stageM0282M154MX33N stageN0219N186N264MicrosatelliteMSS\
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36[^2] Figure 1Analysis of the expression level of 22 TIICs and its correlation in 369 colon cancer cases and 39 normal cases. (**A, B**) Heatmap of 22 TIICs and immune cells between 369 colon cancer cases derived from the TCGA database. (**C**) The correlation matrix of 22 types of TIILs in colon cancer analyzed by Pearson correlation coefficient. (**D**) The differences in the composition of TIIC between normal tissue and colon cancer tissues.Figure 2Correlation analysis between TNM&Stage and 22 TIICs in 369 colon cancer cases. (**A**) Correlation analysis between tumor stage and 22 TIICs expression in 369 colon cancer cases. (**B**) Correlation analysis between node stage and 22 TIICs expression in 369 colon cancer cases. (**C**) Correlation analysis between metastasis stage and 22 TIICs expression in 369 colon cancer cases. (**D**) Correlation analysis between pathologic stage and 22 TIICs expression in 369 colon cancer cases.

LASSO Cox Regression Analysis Was Utilized to Establish an Immune Risk Score {#S0003-S2002}
----------------------------------------------------------------------------

To find a subset of prognosis that was statistically associated with the risk of colon cancer survival, we used a univariate ﻿Cox regression method to analyze 22 immune cells. P\<0.05 was set as the screening criteria. The results indicated that B cells naive, B cells memory, Monocytes, Macrophages M0, Macrophages M1 were prominently associated with colon cancer survival risk ([Table 2](#T0002){ref-type="table"}). Furthermore, LASSO Cox model was performed to construct an immune risk scoring model based on the foresaid five immune cells (Macrophages M0 was finally eliminated by LASSO C﻿ox model). The distribution of immune risk score, patients' survival status and 4 immune cells in colon cancer patients was presented in [Figure 3C](#F0003){ref-type="fig"}[-E](#F0003){ref-type="fig"}, respectively. The correlation between risk scores and clinical indicators is displayed in [Figure 3F](#F0003){ref-type="fig"}, and we found the higher immune risk factor was also associated with pathological T and N stage. Each patient received a risk score according to the model. Based on the median value of the risk score, we divided the patients into high-risk and low-risk groups. The ROC curve revealed that the risk model had a good sensitivity and specificity in predicting survival risk (AUC=0.848, [Figure 4A](#F0004){ref-type="fig"}). The KM curve suggested that patients in the high-risk group had a poor prognosis ([Figure 4B](#F0004){ref-type="fig"}). We also applicated the model in a GEO dataset for validation. As expected, our model showed satisfying AUC in the validation dataset (0.941 for 3-year overall survival (OS) and 0.865 for 5-year OS, [Figure 4C](#F0004){ref-type="fig"}). Similarly, patients with the high-risk also showed poor prognosis in validation dataset ([Figure 4D](#F0004){ref-type="fig"}).Table 2Results of Univariate Cox Regression Analysis for 22 Immune Cells in Colon Cancer PatientsidHRHR.95LHR.95HP valueB cells naive311.03202721.44836110666,793.371850.03615504B cells memory2.16807E+1918,675.810682.52E+340.011880731Plasma cells9.9088806140.00581417516,887.333950.545776925T cells CD83.6906802350.025493891534.28958640.606953156T cells CD4 naive\*\\\\\\\\T cells CD4 memory resting36.20958880.04402482929,781.701790.294609189T cells CD4 memory activated5.849768190.000168512203,070.02140.740535312T cells follicular helper0.0002128151.29E-13351,897.08660.434968265T cells regulatory (Tregs)3.8312736441.61E-05912,942.22020.831615743T cells gamma delta4.64824E-102.80E-347.72909E+140.450124041NK cells resting22.219027919.25E-0653,358,493.740.679102018NK cells activated325.37124271.35E-057,815,492,3650.504657234Monocytes1.71433E+39191,849.96151.53E+730.02351612Macrophages M00.0200330770.0004597920.8728381850.042296692Macrophages M143,538.634823.731631977507,984,906.80.025379661Macrophages M20.0102141395.82E-07179.27616440.357927745Dendritic cells resting5.87793E-082.52E-20137,147.61510.251849586Dendritic cells activated1.54177E-131.96E-421.21361E+160.384840626Mast cells resting321.71191980.00013431770,592,696.20.441073054Mast cells activated0.3663724565.54E-052421.2986620.822963554Eosinophils7.80315E-092.54E-352.3989E+180.548551183Neutrophils173.41617733.55E-108.47016E+130.707327463[^3] Figure 3(**A, B**) LASSO Cox regression model to 4 prognostic factors used to construct immune risk score model (eliminated 1 factor: Macrophages M1). (**C**) Distribution of immune risk scores in colon cancer patients. (**D**) Distribution of survival status in colon cancer patients. (**E**) Distribution of specific risk factors (Macrophages M1, B cells naive, B cells memory and monocytes) in the high- and low-risk groups (divided by median value). (**F**) The correlation between immune risk score and clinical indicators.Figure 4(**A**) ROC curve AUC statistics assess the predictive capability of the immune risk score model (TCGA database). (**B**) Kaplan--Meier survival curves of over survival between high- and low-risk group (TCGA database). (**C**) ROC curve AUC statistics assess the predictive capability of the immune risk score model (independent validation set derived from GEO database, N=856). (**D**) Kaplan--Meier survival curves of over survival between high- and low-risk group (independent validation set derived from GEO database, N=856).

The Immune Risk Scoring Model Was an Independent Factor for Predicting the Prognosis of Colon Cancer {#S0003-S2003}
----------------------------------------------------------------------------------------------------

To explore whether the constructed immune risk scoring model was independent form age, gender, stage, and other clinical pathological parameters, we performed an univariate and multivariate ﻿Cox regression analysis for age, gender, stage, TNM and risk score. In univariate Cox model, pathological T, N stage, pathological stage and high immune risk score were associated with poor survival ([Figure 5A](#F0005){ref-type="fig"}). In multivariate C﻿ox model, only pathological T stage and immune risk score worked as independent predicted factors ([Figure 5B](#F0005){ref-type="fig"}). On the basis of the coefficients of the multivariate ﻿Cox regression analysis, we constructed a nomogram to predict patient survival ([Figure 5C](#F0005){ref-type="fig"}).Figure 5Cox's proportional hazard model of correlative factors in colon cancer patients. (**A**) Univariate Cox regression analysis for seven clinicopathological parameters affecting the overall survival. (**B**) Multivariate Coxregression analysis for seven clinicopathological parameters affecting the overall survival. (**C**) An established nomogram to predict survival based on Cox model.

Discussion {#S0004}
==========

As already told, the immune system plays an important role in the development of cancer, which could recognize and kill cancer cells through adaptive immune response defence. Meanwhile, cancer cells could succeed in escaping the recognition of immune cells via a variety of ways. Tumor micro-environment (TME) was composed of cancer cells, stromal cells, chemokines and cytokines, where these cells could communicate and transmit by direct contact or secretion of related cytokines.[@CIT0013] Studies had shown that cancer prognosis was closely related to TME, especially cancer﻿-infiltrating immune cells.[@CIT0014],[@CIT0015] It is evident that different types of cancers had diverse TIICs subpopulation. Even the same pathological type, TIICs subpopulation could be various among patients. Therefore, it was crucial to investigate the immune﻿-infiltrating cell subsets for the evaluation of risk and tumor prognosis.

We conducted a comprehensive and detailed assessment of immune infiltration in colon cancer, based on the deconvolution of data from a large set of samples. The study revealed the specific TIICs that affected the prognosis of patients with colon cancer, and demonstrated the diversity of immune cells in patients with colon cancer. Separate studies have shown that[@CIT0016]--[@CIT0019] colon cancer is locally infiltrated with various immune cell subgroups, including Macrophages, dendritic cells, NK cells, initial and memory CD8 + T cells, B cells, and different effector CD4 + T cell subsets, such as Th1 cells, Th2 cells, Th17 cells andregulatory T cells (Treg). These characteristic immune cells constituted an individualized "immune signature map" for patients with early colon cancer, and provided new ideas for the subsequent specific immunotherapy for colon cancer. In our research, we aimed to accurately explore the prognostic value of tumor-infiltrating immune cells in patients with colon cancer. Similarly, the results of the difference analysis showed that except for B cells naive, Plasma cells, T cells delta gamma, T cells CD4 memory activated, T cells follicular helper, NK cells resting, NK cells activated, Monocytes, Macrophages M0, Macrophages M2, mast cells resting, mast cells activated, the remaining immune cells had no differential infiltration between normal and colon cancer tissues (p\<0.05).

Additional analysis indicated that B cells naive, B cells memory, Monocytes, Macrophages M0, Macrophages M1 were associated with colon cancer survival risk. Previously, many studies have shown that tumor necrosis factor-α is closely related to the promotion and development of tumors.[@CIT0020],[@CIT0021] Stanilov et al[@CIT0022] have observed that monocytes from patients with advanced cancer secreted significantly more tumor necrosis factor-α than those from patients with early disease. And they believed that monocytes in colon cancer patients are prone to produce higher levels of tumor necrosis factor-α after stimulation, which is related to the survival risk of the disease. Kaler et al recently reported macrophages associated with colon cancer. And they found that macrophages and IL-1 promote Wnt signal transduction in colon cancer cells in a NF-kB-dependent manner. This suggested that the pro-inflammatory cytokines produced by macrophages could enhance the transcription activity of tumor cells and promote the growth of colon cancer cells.[@CIT0023],[@CIT0024] Their results demonstrated that monocytes and macrophages promoted colon cancer cell growth, which was consistent with our findings that increased monocytes infiltration as well as macrophages were associated with poor prognosis of colon cancer.

Furthermore, a LASSO ﻿Cox regression method was used to construct an immune risk scoring model for these four immune cells. KM curve indicated that patients in high-risk were associated with poor outcomes (p\<0.001). ROC curve indicated that the immune risk scoring model was reliable in predicting survival risk (AUC = 0.848). We conducted a multivariate ﻿Cox regression analysis on risk score, age, gender, stage and TNM stages. Results showed that the immune risk score model was an independent factor for predicting the prognosis of colon cancer (hazard ratio (HR) = 5.017, 95％confidence interval (CI) =2.336--10.777; P\<0.001). At present, effective biomarkers for predicting the prognosis of colon cancer still lack all over the world.[@CIT0025],[@CIT0026] Clinically, the prognosis was mainly based on the clinical stage and histopathological classification, but in previous studies, it has been found that patients with the same clinical stage and pathological type of colon cancer had different response and prognosis.[@CIT0027],[@CIT0028] Therefore, finding effective prognostic specific TIICs has important clinical value for improving the prognosis of colon cancer. Ultimately, a nomogram was established to comprehensively predict the survival of colon cancer patients with the results of multivariate ﻿Cox regression analysis.

Several previous studies have explored the role of immune cells in colon cancer through bioinformatics methods. In 2018, based on the systematic evaluation of the immune status of patients with stage I--III colon cancer, Zhou et al[@CIT0010] compared the immune cell composition of 870 patients with colon cancer and 70 normal controls. A diagnostic model named Diagnostic Immune Risk Score (dIRS) and a prognostic immune risk score (pIRS) were constructed. Unfortunately, they did not evaluate stage 4 colon cancer. It should be noted that we included patients with stage 4 colon cancer and established an immune risk score using four immune cells, which show promising new features for the diagnosis and prognosis prediction of colon cancer. To reveal the important relationship between immune invasion of colon cancer and clinical results, Yongfu et al[@CIT0029] analyzed and evaluated the proportion of tumor﻿-infiltrating immune cell subsets present in 22 colon cancers. However, they did not establish a model to predict survival and prognosis, which was their shortcomings. Ge et al[@CIT0030] explored the expression of immune cells and immune-related genes in the tumor microenvironment of colon cancer. They analyzed the infiltration of 22 immune cells in the TME and the expression of immune-related genes in 404 colon cancer and 40 adjacent non-tumorous tissues. Immune-related genes were selected to establish a prognostic model for TNM staging, but the prediction model was not externally verified in the GEO cohort. We not only used immune-related cells to build an immune risk scoring model, but also applied the model in a GEO dataset for validation. Pleasantly, our model showed satisfying AUC in the validation dataset (0.941 for 3-year OS and 0.865 for 5-year OS). Simultaneously, in [Figure 2](#F0002){ref-type="fig"}, we showed the landscape of the distribution of immune cells in different clinical stages and pathological grade colon cancer, which was not described before. Absolutely, our research inevitably had certain limitations. The four validation set data are all from Europe, and thus these results cannot be directly extrapolated to other ethnic groups. The applicability of the model in the Asian population still needs to be verified.

In summary, our study sheds light on the utility of immune cells in the prognosis of colon cancer. The constructed immune risk scoring model is reliable in predicting the prognosis of colon cancer, and this risk scoring model is an independent influencing factor for the prognosis of colon cancer. With the rapid development of high-throughput technology, we have confidence to believe that our immune risk scoring model have great potential in clinical practice. And it may have critical value for exploring new anti-cancer immunodiagnosis and treatment strategies.
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